Welcome to our dedicated page for Cyclacel Phar Pr news (Ticker: CYCCP), a resource for investors and traders seeking the latest updates and insights on Cyclacel Phar Pr stock.
Cyclacel Pharmaceuticals Inc. (CYCCP) is a clinical-stage biopharmaceutical company advancing novel cancer therapies through targeted cell cycle inhibition. This news hub provides investors and researchers with timely updates on the company’s progress in developing CDK and PLK inhibitors for oncology applications.
Access consolidated updates on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated feed includes essential announcements regarding:
• Phase 1/2 clinical trial results for fadraciclib and plogosertib
• Regulatory submissions and FDA communications
• Intellectual property developments and patent grants
• Research collaborations with academic institutions
Bookmark this page for direct access to primary source materials and analysis-neutral reporting on Cyclacel’s progress in precision oncology. Check regularly for updates on the company’s efforts to address unmet needs in solid tumors and hematologic malignancies through cell cycle-targeted therapies.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced its participation in two upcoming investor conferences. The Oppenheimer 33rd Annual Healthcare Conference will be held virtually from March 13-15, 2023, featuring a fireside chat on March 13 at 10:00 am ET led by Spiro Rombotis. The 35th Annual Roth Conference takes place in Dana Point, CA from March 12-14, 2023, with a fireside chat on March 13 at 3:00 pm PT presented by Paul McBarron. Cyclacel is focused on developing innovative cancer treatments targeting cell cycle and transcriptional regulation.
Cyclacel Pharmaceuticals reported its 2022 financial results and outlined key objectives for 2023. The company aims to advance oral fadraciclib into Phase 2 trials and explore the potential of oral plogosertib. They anticipate multiple data readouts including interim results from their Phase 1/2 studies. As of December 31, 2022, cash and equivalents were $18.3 million, down from $36.6 million in 2021, with a net loss of $21.2 million. R&D expenses rose due to ongoing trials for both drug candidates. The company believes it can fund operations through the fourth quarter of 2023.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) is set to announce its fourth quarter and full year 2022 financial results on March 6, 2023, at 4:30 PM ET. Following the announcement, a conference call will be hosted to discuss the results and company updates. Investors can access the call via toll-free numbers or webcasts. Cyclacel focuses on developing innovative cancer therapies, including the CDK2/9 inhibitor fadraciclib and the PLK1 inhibitor plogosertib. The company’s strategy aims to establish a diversified pipeline addressing oncology and hematology indications.
FAQ
What is the current stock price of Cyclacel Phar Pr (CYCCP)?
What is the market cap of Cyclacel Phar Pr (CYCCP)?
